生物医药
Search documents
2026,投资人把“卡脖子”清单,变成投资清单
Sou Hu Cai Jing· 2026-02-06 07:07
围绕这些问题,融中第十五届中国资本年会暨大虹桥科创投资大会上,以"技术迭代,VC投资的创新模式"为题,进行了专场论坛讨论。中科育成投资董 事长、总经理陈静鹤,金投致源董事长方健,天图投资创始合伙人、CEO冯卫东,唐兴资本创始人、董事长宫蒲玲,创维投资创始合伙人马友杰,达晨财 智合伙人、执行总裁齐慎,创东方投资总裁、管理合伙人阮庆国,永鑫方舟董事长兼管理合伙人韦勇参与了论坛讨论,浙科投资董事长顾斌作为论坛主 持。 敢重仓,才是真拥抱 当前,股权投资行业正步入认知回归与能力重塑的"淬炼期":长期资本持续扩容,耐心资本日益成为支撑科技创新的核心力量,投资机构聚焦硬科技与战 略性新兴产业,深化布局、深挖价值;多元退出与投资路径不断拓展,加速构建"投早、投小、投科技"的良性生态;政府引导基金与国资投资平台已成长 为产业发展的"稳定器"与"助推器",携手产业方及各类资本,共建深度融合、共创共享的产融生态。 作为"十五五"规划的开局之年,融中第十五届中国资本年会暨大虹桥科创投资大会应势启幕。本届峰会以《淬·炼》为主题,汇聚政府部门代表、头部投 资机构、顶尖经济学家及行业领军企业,于新年伊始展开深度对话,共议投资趋势、产业发 ...
20cm速递|科创100ETF国泰(588120)涨超0.7%,机构关注制造业与科技景气扩散
Mei Ri Jing Ji Xin Wen· 2026-02-06 07:07
Core Viewpoint - The technology and manufacturing sectors are experiencing a positive expansion in economic conditions, with a notable focus on the AI industry cycle driving growth beyond just the tech sector [1] Group 1: Market Performance - The Cathay Innovation 100 ETF (588120) rose over 0.7% on February 6, indicating institutional interest in the manufacturing and technology sectors [1] - The Cathay Innovation 100 ETF tracks the Innovation 100 Index (000698), which includes 100 securities with large market capitalization and good liquidity from the Sci-Tech Innovation Board [1] Group 2: Sector Analysis - In the TMT (Technology, Media, and Telecommunications) sector, the pre-earnings expectations for electronics and communications remain stable for 2024, while improvements are seen in computing and media [1] - The AI industry cycle is not only impacting the tech sector but is also spreading to midstream manufacturing sectors such as machinery, chemicals, power equipment, and military [1] Group 3: Profitability Trends - Export growth is contributing to profitability across various industries, with performance improvements being validated in most sectors [1] - The current economic landscape is characterized by a "K-shaped" recovery in profitability, where high-quality companies are seeing a recovery in earnings first, while weaker firms are accelerating their exit from the market [1]
港股午评|恒生指数早盘跌1.13% 三只新股挂牌首日均上涨
智通财经网· 2026-02-06 04:04
Group 1 - The Hang Seng Index fell by 1.13%, down 304 points, closing at 26,580 points, while the Hang Seng Tech Index decreased by 0.47% [1] - Three new stocks were listed: Dazhu CNC (03200) rose by 18%, Muyuan Foods (02714) increased by 4.72%, and Zhuozheng Medical (02677) surged by 34% [1] - Zhongxin Hang (03931) saw a 3.83% increase, with a 630% year-on-year growth in commercial battery deliveries and plans for full circulation of H-shares [1] - Long Resources (01712) experienced a 30% intraday surge, with expected net profit growth of up to 3.8 times year-on-year [1] - Changfei Optical Fiber (06869) rose over 10%, with institutions optimistic about fiber optic manufacturers benefiting from price increases [1] - Nuo Cheng Jianhua (09969) increased by over 11%, achieving profitability for the first time due to the volume of Obutinin and growth in BD revenue [1] - Nine Dragons Paper (02689) rose over 5%, benefiting from improved self-sufficiency in wood pulp and favorable industry supply-demand dynamics [1] - Jiaxin International Resources (03858) increased by over 5%, supported by supply contraction driving up tungsten prices [1] Group 2 - Fuhong Hanlin (02696) rose over 5% after licensing rights to Hanshuo in Japan to Eizai for a total transaction amount of approximately $388 million [2] Group 3 - Tongda Group (00698) increased by over 6%, expecting to turn a profit with a maximum earnings forecast of 125 million HKD for the previous year [3] - NIO-SW (09866) rose over 5%, marking its first quarterly profit with an expected adjusted operating profit of up to 1.2 billion CNY for the last quarter [3] - Cryptocurrency ETFs and related stocks continued to decline, with Bitcoin dropping below $65,000 amid ongoing sell-offs in the crypto market [3]
亿腾嘉和午前涨超9% 股份简称今日起正式更名为“亿腾嘉和”
Zhi Tong Cai Jing· 2026-02-06 03:40
亿腾嘉和(06998)午前涨超9%,截至发稿,涨8.68%,报2.88港元,成交额692.59万港元。 值得注意的是,嘉和生物上月宣布,拟不时于公开市场购回公司股份。公司自1月28日起连续多日回购 股份,截至2月5日,公司累计回购金额约1851.7万港元,累计回购724.5万股股份。 消息面上,12月30日,亿腾医药以反向收购方式完成与嘉和生物的换股合并和上市。此次反向收购的达 成,标志着亿腾嘉和的正式成立,并在战略整合与发展上迈入全新阶段。嘉和生物-B中文股份简称则 由"嘉和生物"更改为"亿腾嘉和",自2026年2月6日起上午九时正起生效。 ...
2026年省重点建设项目出炉,共计389个项目 长沙一批重点项目入选
Chang Sha Wan Bao· 2026-02-06 03:21
社会民生方面,将重点推进长株潭生态绿心"一厅一道"生态绿道、长沙奥体中心、湖南省体育训练基地 (含国家训练基地)建设项目和湖南体育职业学院整体搬迁项目、中南大学湘雅医院国家医学中心建设 项目等。 生态环保方面,将重点推进全省全域土地综合整治工程、沿江干支流污水厂网河湖一体化综合治理项 目、城市黑臭水体治理项目、全省大气污染防治能力建设有关项目以及长沙市新开铺污水处理厂厂网一 体质效提升工程等。 基础设施项目包括交通网项目67个、水利网项目13个、能源网项目24个、新基建项目10个、物流网项目 32个及6个其他项目。湖南将加快推进长沙至赣州铁路(湖南段)、邵阳至永州铁路、铜仁至吉首铁路 (湖南段)、宜昌至常德铁路(湖南段)、永州至清远至广州铁路(湖南段)、黔江至吉首铁路(湖南 段)等铁路项目,G4京港澳高速长沙广福至株洲王十万(朱亭)段扩容工程、G4京港澳高速岳阳龙湾 至长沙广福段扩容工程、G9907浏阳沙市至宁乡高速公路(长沙北横高速)、许广高速茶亭互通至长沙 绕城高速公路、浏阳至江背高速公路项目、长沙至吉首高速公路长沙至安化段等高速公路,以及长沙机 场改扩建工程、低空经济产业配套基础设施项目(长沙坪塘通用机 ...
深圳重磅!市值超19万亿元!
Zhong Guo Ji Jin Bao· 2026-02-06 02:57
Core Insights - Shenzhen has reached 600 listed companies with a total market capitalization exceeding 19 trillion yuan, showcasing its commitment to innovation and high-quality development [1] - The number of Shenzhen's domestic listed companies has grown by 35.03% during the 14th Five-Year Plan period, with a total market value of 12.59 trillion yuan as of October 2025, accounting for over 10% of the total market value of A-share listed companies [2] - Shenzhen's listed companies are leading in technological innovation, with over half of the companies on the ChiNext and Sci-Tech Innovation Board focusing on high-tech sectors [3] Group 1: Company Growth and Performance - Shenzhen's listed companies contributed over 20 billion yuan in taxes in the last five years and over 35 billion yuan in the last decade, supporting regional employment with over 4 million employees [2] - In the first three quarters of 2025, Shenzhen's listed companies achieved a total revenue of 5.20 trillion yuan and a net profit of 457.8 billion yuan, with revenue growth of 7.36% and net profit growth of 3.98%, surpassing the national average [2] - There are 20 companies in Shenzhen with a market value exceeding 100 billion yuan, with 8 of them forecasting positive earnings for 2025, totaling an expected profit of 253.9 billion yuan [2] Group 2: Technological Innovation - Shenzhen's listed companies are focusing on technological innovation, with 216 companies on the ChiNext and Sci-Tech Innovation Board, representing over half of the total, the highest among major cities in China [3] - The R&D intensity of 162 strategic emerging industry companies in Shenzhen is as high as 7%, with BYD leading with over 54 billion yuan in R&D investment [3] - Notable advancements include Hanon Medical's development of China's first ECMO system, which received EU MDR certification, and the successful R&D of key components for humanoid robots by Huichuan Technology [3][4] Group 3: Capital Market Innovations - Shenzhen companies are leveraging capital market innovations, with several becoming the first in their respective fields to list, such as Beixin Life, the first medical device company under the new Sci-Tech Innovation Board standards [6] - The city has seen a rise in "first stocks" in niche markets, contributing fresh capital to the market while meeting their financing needs [6] - Upcoming listings include Yingstone Innovation, expected to be the first global smart imaging company, and Youbixuan, a humanoid robot company, indicating a strong pipeline of innovative firms [6][7] Group 4: Future Prospects - Shenzhen has cultivated a robust pipeline of quality tech companies poised for future listings, with high-tech products like drones and 3D printers showing significant export growth [8][9] - The export of high-tech products from Shenzhen is projected to grow by 10.1% in 2025, driven by innovative products from companies like DJI and others [9]
“新质领航 创启未来” 2025 科技创新峰会成功举办——共绘新质生产力发展蓝图
Jing Ji Guan Cha Wang· 2026-02-06 02:53
Core Insights - The 2025 Technology Innovation Summit, organized by Economic Observer, focused on advanced fields such as artificial intelligence, digital transformation, robotics, and biomedicine, aiming to explore new productivity development paths and share innovative practices for industrial upgrading and high-quality economic development [1] Group 1: Event Overview - The summit gathered top industry experts, renowned entrepreneurs, and representatives from investment institutions to discuss the acceleration of emerging sectors like generative AI, domestic chips, commercial aerospace, and humanoid robots, which are becoming new engines for economic growth [2] - Economic Observer aims to create a platform for deep integration of entrepreneurial wisdom, academic insights, and capital power to address development challenges and foster innovation consensus [2] Group 2: Artificial Intelligence Innovations - Yang Ting, Chief Scientist of AI at AsiaInfo, introduced a new security paradigm called "Intelligent Linkage" that utilizes AI XDR systems to achieve a 100% response rate in major events [2] - Hikvision's application of IoT perception and AI technology in industrial quality management won the 2025 China Quality Award, enhancing quality control across multiple industries [3] - Ant Group's "Lingguang" app has generated over 12 million flash applications, enhancing user experience in various sectors through its core features [5] - JD Technology's large model products have been applied in government and enterprise collaboration, creating over 30,000 high-value digital employees [7] - XianDuo Intelligent's predictive maintenance solution has saved clients over 10 million yuan annually by predicting equipment failures 7-15 days in advance [10] - Kingdee's AI-native solutions have served over 7.4 million clients, focusing on digital transformation to address industry pain points [12] Group 3: Robotics and Biomedicine - Yunji Technology's approach to developing intelligent agents through collaboration between robots and AI has transformed hospital services [14] - The AI4S industry dialogue highlighted AI's role in drug development, emphasizing its ability to lower research barriers and enhance efficiency across all stages of drug discovery [18] Group 4: Recognition and Future Directions - The summit concluded with the release of the "New Quality 100" innovation enterprise list, showcasing exemplary companies in AI, biomedicine, semiconductors, and intelligent manufacturing [19] - The event aimed to establish benchmarks for new productivity and encourage more enterprises to engage in technological innovation, contributing to the construction of a modern industrial system [19]
重磅利好!市级八部门联合赋能,助推昌平医药产业跃升
Bei Jing Ri Bao Ke Hu Duan· 2026-02-06 02:39
聚焦AI+医药健康创新赋能,政策从算力保障与场景融合两方面双向发力筑牢技术应用根基。算力支撑 方面,将推动中关村生命科学园三期等重点区域部署生物医药专业化智算设施,为创新主体提供高效算 力保障;AI融合方面,支持医疗卫生机构与垂类大模型企业联合挂牌AI实体医院,构建 "AI+医疗"产业 协同生态,加速技术落地应用。 01 建平台、创机制、设基金 市区联动激活原始创新 《若干措施》由北京市科委、中关村管委会,北京市人才局,北京市发改委,北京市教委,北京市经信 局,北京市卫健委,北京市医保局,北京市药监局8部门联合昌平区政府共同印发,以"培育高质量产业 生态"为核心,全方位优化创新环境。 近日,《关于支持昌平区医药健康产业高质量发展的若干措施(2026-2028年)》(以下简称《若干措 施》)正式印发,为昌平区医药健康产业注入全方位、多层次的政策红利,推动产业实现创新提效、发 展提质、开放提级的跨越式发展。 强化产业发展支撑,以载体升级与服务优化双轮驱动产业生态提质。在产业载体与服务升级上,一方面 持续打造中关村(昌平)智能眼科医工产业园等示范园区,加快未来美城、脑科学与脑机接口产业集聚 区、合成生物制造产业集聚 ...
600家上市公司背后:深圳如何实现从速度到质量的新跨越?
Nan Fang Du Shi Bao· 2026-02-06 02:35
Group 1 - Shenzhen's total number of listed companies has officially surpassed 600, comprising 426 domestic and 174 overseas companies, with a total market capitalization exceeding 19 trillion yuan [2] - During the 14th Five-Year Plan period, the number of domestic listed companies in Shenzhen grew by 35.03%, with a total market value of 12.59 trillion yuan as of January 2026, ranking second among major cities in China [2] - In the first three quarters of 2025, listed companies in Shenzhen achieved a cumulative operating income of 5.20 trillion yuan, a year-on-year increase of 7.36%, outpacing the national average [2] Group 2 - Approximately 80% of newly listed companies in Shenzhen are from the Sci-Tech Innovation Board and the Growth Enterprise Market, highlighting a strong focus on technological innovation [3] - The semiconductor and integrated circuit industry clusters have emerged as significant contributors, with companies like Zhongke Feicai and Laplace rapidly rising in the market [3] - Shenzhen's artificial intelligence and robotics sectors demonstrate global competitiveness, with companies like UBTECH and Huichuan Technology leading the way [3] Group 3 - The cluster of companies in new energy and green technology reflects Shenzhen's industrial transformation, with major players like BYD and Shihang New Energy leading the charge [4][5] - BYD's annual R&D investment exceeds 54 billion yuan, showcasing Shenzhen's commitment to core technology development [5] - The biopharmaceutical sector is also making strides, with companies like Beixin Life and Hanno Medical achieving significant technological breakthroughs [5] Group 4 - Shenzhen's capital market is characterized by a multi-dimensional structure, with a total market capitalization of 12.59 trillion yuan, accounting for over 10% of the total A-share market [6] - In the first three quarters of 2025, main board companies experienced revenue and net profit growth rates of 7.22% and 4.84%, respectively [6] - The overseas listing channel has become a significant growth driver, with 38 new overseas listed companies from Shenzhen between 2023 and 2025 [6] Group 5 - The active M&A market in Shenzhen has accelerated industrial upgrades, with 146 M&A transactions completed in 2025, totaling 86.645 billion yuan [7] - Companies like Luxshare Precision and China Resources Sanjiu are examples of successful acquisitions that enhance their competitive capabilities [7] - The capital market plays a crucial role in promoting high-level circulation among technology, capital, and industry [7] Group 6 - Recent listings of companies like Dongpeng Beverage and Beixin Life reflect the diverse sectors represented in Shenzhen's economy, including consumer goods, hard technology, high-end manufacturing, and modern services [8][9] - Dongpeng Beverage's growth illustrates the path of regional brands becoming national enterprises through capital markets [8] - Beixin Life's listing signifies the capital market's support for innovative biopharmaceutical companies [9] Group 7 - Shenzhen's comprehensive support ecosystem for businesses includes a clear growth path and tailored policies for different types of enterprises [10] - The city has over 20,000 national high-tech enterprises and 1,333 national specialized "little giant" companies, leading the nation in both total and incremental growth [10] - Financial support networks have facilitated over 2.8 trillion yuan in direct financing for Shenzhen enterprises during the 14th Five-Year Plan period [11] Group 8 - Shenzhen's capital market is transitioning from quantity accumulation to structural optimization and quality enhancement, with strategic emerging industries expected to become the main force in future listings [12] - The implementation of the "Shenzhen Action Plan for Promoting High-Quality Development of Mergers and Acquisitions" will enrich the cases of mergers and acquisitions for listed companies [13] - Shenzhen's R&D investment has significantly increased, reaching 2.453 trillion yuan by 2024, with an R&D intensity of 6.67%, ranking first among cities in China [13]
花园生物股价涨5.42%,南方基金旗下1只基金位居十大流通股东,持有347.85万股浮盈赚取340.89万元
Xin Lang Cai Jing· 2026-02-06 02:17
Group 1 - Garden Biologics' stock increased by 5.42%, reaching 19.05 CNY per share, with a trading volume of 245 million CNY and a turnover rate of 2.47%, resulting in a total market capitalization of 10.353 billion CNY [1] - The company, Zhejiang Garden Biologics Co., Ltd., was established on December 18, 2000, and went public on October 9, 2014. Its main business focuses on developing, producing, and selling products related to a complete vitamin D3 industry chain [1] - The revenue composition of the company includes vitamin products at 47.41%, pharmaceuticals at 30.22%, lanolin and its derivatives at 20.93%, sales of raw materials and others at 1.01%, rental income at 0.31%, other trade products at 0.10%, and medical devices at 0.01% [1] Group 2 - Among the top circulating shareholders of Garden Biologics, a fund under Southern Fund holds a position. The Southern CSI 1000 ETF (512100) reduced its holdings by 48,400 shares in the third quarter, now holding 3.4785 million shares, which is 0.65% of the circulating shares [2] - The Southern CSI 1000 ETF (512100) was established on September 29, 2016, with a latest scale of 78.996 billion CNY. Year-to-date returns are 6.21%, ranking 1574 out of 5564 in its category; the one-year return is 39%, ranking 1777 out of 4288; and since inception, the return is 21.47% [2] - The fund manager of Southern CSI 1000 ETF (512100) is Cui Lei, who has been in the position for 7 years and 93 days, managing total assets of 137.02 billion CNY. The best fund return during this period is 279.97%, while the worst is -15.93% [2]